New ion-exchange chromatography media are more tolerant of varying conditions, making it possible to eliminate process steps.
Ion-exchange chromatography is often a crucial component of the downstream processing of biopharmaceuticals. Innovative new exchangers with new ligand chemistries are making it possible to increase selectivity and capacity. Some also are tolerant of high salt conditions, enabling the elimination of some preparative steps. Jim Powell, business development manager with Asahi Kasei Bioprocess, Estelle Zelter, global product manager of ion-exchange chromatography at EMD Millipore, and Sylvio Bengio, head of scientific communications for the global chromatography group at Pall Life Sciences, spoke with Cynthia Challener, editor of the Pharmaceutical Sciences, Manufacturing & Marketplace Report, about recent developments in ion-exchange chromatography technology that are benefiting their pharmaceutical customers.
Capacity and selectivity are key
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.